Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Nicola GaynorAlfonso BlancoStephen F MaddenBarry MoranJean M FletcherDamien KaukonenJavier Sánchez RamírezAlex J EustaceMartina S J McDermottAlexandra CanoniciSinead ToomeyAusra TeiserskieneBryan T HennessyNorma O'DonovanJohn CrownDenis M CollinsPublished in: British journal of cancer (2023)
PBMCs display altered phenotype and function following completion of neo-adjuvant treatment. Anti-PD-1-responsive PBMCs in ex vivo ADCC assays may be a biomarker of treatment response.